Genentech gets FDA nod for Tecentriq combination to treat advanced melanoma
The Tecentriq combination helped people live longer without their disease worsening or progression-free survival (PFS) than placebo plus…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
31 Jul 20
The Tecentriq combination helped people live longer without their disease worsening or progression-free survival (PFS) than placebo plus…
31 Jul 20
STELARA was previously approved for moderate to severe plaque psoriasis in adults, which is now expanded to include…
30 Jul 20
The European regulatory approval was based on Phase 3 SOLAR-1 trial, which showed that Piqray plus fulvestrant almost…
22 Jul 20
QUTENZA is a topical, non-systemic, non-opioid pain treatment to deliver prescription strength capsaicin directly into the skin
16 Jul 20
The EC approval for nintedanib follows the positive opinion from the Committee for Medicinal Products for Human Use…
14 Jul 20
The two investigational vaccine candidates, BNT162b1 and BNT162b2, are part of the Pfizer and BioNTech’s BNT162 mRNA-based vaccine…
13 Jul 20
The trial initially enrolled 18 volunteers, for whom the Covid-19 vaccine was dosed on 18 June 2020 and…
09 Jul 20
Lynparza is an advanced PARP inhibitor and a targeted treatment designed to block the DNA damage response (DDR)…
08 Jul 20
The approval indicated the drug for uncontrolled asthma in patients who experienced one or more asthma exacerbations in…
06 Jul 20
The conditional marketing authorisation was granted based on the US National Institute of Allergy and Infectious Diseases’ global…